Literature DB >> 29440146

A DDX31/Mutant-p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer.

Kei Daizumoto1,2, Tetsuro Yoshimaru1, Yosuke Matsushita1, Tomoya Fukawa1,2, Hisanori Uehara3, Masaya Ono4, Masato Komatsu1, Hiro-Omi Kanayama2, Toyomasa Katagiri5.   

Abstract

The p53 and EGFR pathways are frequently altered in bladder cancer, yet their contributions to its progression remain elusive. Here we report that DEAD box polypeptide 31 (DDX31) plays a critical role in the multistep progression of muscle-invasive bladder cancer (MIBC) through its sequential interactions with mutant p53 (mutp53) and EGFR. In early MIBC cells, nuclear DDX31-bound mutp53/SP1 enhanced mutp53 transcriptional activation, leading to migration and invasion of MIBC. Cytoplasmic DDX31 also bound EGFR and phospho-nucleolin in advanced MIBC, leading to EGFR-Akt signaling activation. High expression of both cytoplasmic DDX31 and p53 proteins correlated with poor prognosis in patients with MIBC, and blocking the DDX31/NCL interaction resulted in downregulation of EGFR/Akt signaling, eliciting an in vivo antitumor effect against bladder cancer. These findings reveal that DDX31 cooperates with mutp53 and EGFR to promote progression of MIBC, and inhibition of DDX31/NCL formation may lead to potential treatment strategies for advanced MIBC.Significance: DDX31 cooperates with mutp53 and EGFR to promote progression of muscle invasive bladder cancer. Cancer Res; 78(9); 2233-47. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29440146     DOI: 10.1158/0008-5472.CAN-17-2528

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  MIR-300 in the imprinted DLK1-DIO3 domain suppresses the migration of bladder cancer by regulating the SP1/MMP9 pathway.

Authors:  Huaqing Yan; Jiangfeng Li; Yufan Ying; Haiyun Xie; Hong Chen; Xin Xu; Xiangyi Zheng
Journal:  Cell Cycle       Date:  2018-12-18       Impact factor: 4.534

2.  Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.

Authors:  Yun Ye; Su-Liang Li; Sheng-Yu Wang
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

3.  LincRNA-p21 suppresses glutamine catabolism and bladder cancer cell growth through inhibiting glutaminase expression.

Authors:  Qun Zhou; Hengji Zhan; Fan Lin; Yuhan Liu; Kang Yang; Qunjun Gao; Mengting Ding; Yuchen Liu; Weiren Huang; Zhiming Cai
Journal:  Biosci Rep       Date:  2019-04-12       Impact factor: 3.840

4.  p53/PCDH17/Beclin-1 Proteins as Prognostic Predictors for Urinary Bladder Cancer.

Authors:  Liuxi Chen; Ying Liu; Qi Zhang; Mingming Zhang; Xuemeng Han; Qiujie Li; Tian Xie; Qibiao Wu; Xinbing Sui
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

5.  EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR.

Authors:  Anbang Wang; Aimin Jiang; Xinxin Gan; Zheng Wang; Jinming Huang; Kai Dong; Bing Liu; Linhui Wang; Ming Chen
Journal:  Biomed Res Int       Date:  2020-12-22       Impact factor: 3.411

6.  Systematic analysis of the function and prognostic value of RNA binding proteins in Colon Adenocarcinoma.

Authors:  Xuewei Qi; Zeyu Liu; Qiaoli Zhang; Ming Yang; Yuxiang Wan; Jinchang Huang; Lin Xu
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

7.  The relationship between urologic cancer outcomes and national Human Development Index: trend in recent years.

Authors:  Xiao-Fang Xia; Yi-Qiu Wang; Shi-Yi Shao; Xin-Yu Zhao; Shi-Geng Zhang; Zhong-Yi Li; Yi-Chu Yuan; Nan Zhang
Journal:  BMC Urol       Date:  2022-01-10       Impact factor: 2.264

8.  Dysregulation of tumor microenvironment promotes malignant progression and predicts risk of metastasis in bladder cancer.

Authors:  Ji Liu; Zongtai Zheng; Wentao Zhang; Moxi Wan; Wenchao Ma; Ruiliang Wang; Yang Yan; Yadong Guo; Junfeng Zhang; Wei Li; Xudong Yao
Journal:  Ann Transl Med       Date:  2021-09

9.  Clinical impact of copy number variation changes in bladder cancer samples.

Authors:  Victoria Spasova; Boris Mladenov; Simeon Rangelov; Zora Hammoudeh; Desislava Nesheva; Dimitar Serbezov; Rada Staneva; Savina Hadjidekova; Mihail Ganev; Lubomir Balabanski; Radoslava Vazharova; Chavdar Slavov; Draga Toncheva; Olga Antonova
Journal:  Exp Ther Med       Date:  2021-06-24       Impact factor: 2.447

Review 10.  Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.

Authors:  Milena Matuszczak; Maciej Salagierski
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.